Blinded Sunitinib Malate


Combined with:

Blinded *NO Subject Drug
Blinded *Placebo

Indications and Reactions:

Role Indications Reactions
Primary
Prostate Cancer 32.2%
Colorectal Cancer 11.0%
Hypertension 9.1%
Non-small Cell Lung Cancer 8.8%
Pain 6.8%
Renal Cell Carcinoma 6.6%
Colorectal Cancer Metastatic 3.6%
Prophylaxis 2.7%
Nausea 2.5%
Bone Pain 2.3%
Diabetes Mellitus 2.2%
Insomnia 1.6%
Depression 1.5%
Metastases To Bone 1.5%
Diarrhoea 1.4%
Constipation 1.3%
Lung Neoplasm Malignant 1.3%
Hypercholesterolaemia 1.3%
Prostate Cancer Metastatic 1.3%
Transitional Cell Carcinoma 1.1%
Death 10.2%
Sepsis 8.2%
Urinary Tract Infection 7.5%
Vomiting 7.5%
Pneumonia 6.1%
Renal Failure Acute 6.1%
Hyponatraemia 5.4%
Thrombocytopenia 5.4%
Ileus 4.8%
Myocardial Infarction 4.8%
Pyrexia 4.8%
Gastrointestinal Haemorrhage 4.1%
Anal Abscess 3.4%
Cerebral Ischaemia 3.4%
Diverticular Perforation 3.4%
Intestinal Obstruction 3.4%
Rectal Ulcer 3.4%
Acute Myocardial Infarction 2.7%
Axonal Neuropathy 2.7%
Cerebrovascular Accident 2.7%
Secondary
Colorectal Cancer 21.1%
Prostate Cancer 19.3%
Non-small Cell Lung Cancer 11.9%
Renal Cell Carcinoma 8.6%
Colorectal Cancer Metastatic 8.0%
Pain 5.0%
Hypertension 4.3%
Prophylaxis 3.9%
Diabetes Mellitus 3.1%
Nausea 2.2%
Non-small Cell Lung Cancer Metastatic 1.7%
Metastases To Bone 1.6%
Renal Cancer 1.5%
Lung Neoplasm Malignant 1.4%
Diarrhoea 1.3%
Hypercholesterolaemia 1.2%
Constipation 1.1%
Benign Prostatic Hyperplasia 1.0%
Cancer Pain 1.0%
Hepatitis B 1.0%
Vomiting 15.8%
Death 11.3%
Sepsis 6.0%
Urinary Tract Infection 6.0%
Neutropenia 5.3%
Renal Failure Acute 5.3%
Anal Abscess 4.5%
Peripheral Sensory Neuropathy 4.5%
Subcutaneous Abscess 4.5%
Thrombocytopenia 4.5%
Hypomagnesaemia 3.8%
Hyponatraemia 3.8%
Respiratory Failure 3.8%
Sudden Cardiac Death 3.8%
General Physical Health Deterioration 3.0%
Intestinal Ischaemia 3.0%
Intestinal Obstruction 3.0%
Myocardial Infarction 3.0%
Tumour Lysis Syndrome 3.0%
Agitated Depression 2.3%

Drug Data